GeneOne Life Science Inc Total Liabilities
GeneOne Life Science Inc total liabilities. Based on the latest financial reports, GeneOne Life Science Inc (011000) has total liabilities worth ₩80.13 Billion KRW (≈ $54.30 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GeneOne Life Science Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of GeneOne Life Science Inc (2009–2025)
Total liabilities of GeneOne Life Science Inc from 2009 to 2025. This chart illustrates how GeneOne Life Science Inc's total liabilities have evolved over time, based on quarterly financial data. Explore GeneOne Life Science Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
GeneOne Life Science Inc Competitors by Total Liabilities
The table below lists competitors of GeneOne Life Science Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gyeongnam Steel Co. Ltd
KQ:039240
|
Korea | ₩45.20 Billion |
|
Myomo Inc
NYSE MKT:MYO
|
USA | $27.75 Million |
|
Rockhaven Resources Ltd
V:RK
|
Canada | CA$3.60 Million |
|
NUREXONE BIOLOGIC INC.
F:J90
|
Germany | €1.32 Million |
|
Velocity Minerals Ltd
V:VLC
|
Canada | CA$26.61 Million |
|
Azimut Exploration Inc.
V:AZM
|
Canada | CA$6.74 Million |
|
Monalisa
KO:012690
|
Korea | ₩15.67 Billion |
|
Panstar Enterprise Co.Ltd
KQ:054300
|
Korea | ₩58.94 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down GeneOne Life Science Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is GeneOne Life Science Inc's balance sheet.
Liquidity & Leverage Metrics
GeneOne Life Science Inc Total Liabilities Ratios Explained
GeneOne Life Science Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeneOne Life Science Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeneOne Life Science Inc (2009–2025)
The table below shows the annual total liabilities of GeneOne Life Science Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩78.31 Billion ≈ $53.07 Million |
+19.14% |
| 2024-12-31 | ₩65.73 Billion ≈ $44.54 Million |
+66.33% |
| 2023-12-31 | ₩39.52 Billion ≈ $26.78 Million |
-4.53% |
| 2022-12-31 | ₩41.40 Billion ≈ $28.05 Million |
-6.01% |
| 2021-12-31 | ₩44.04 Billion ≈ $29.85 Million |
+15.71% |
| 2020-12-31 | ₩38.06 Billion ≈ $25.79 Million |
+40.49% |
| 2019-12-31 | ₩27.09 Billion ≈ $18.36 Million |
+36.24% |
| 2018-12-31 | ₩19.89 Billion ≈ $13.48 Million |
+118.67% |
| 2017-12-31 | ₩9.09 Billion ≈ $6.16 Million |
-69.49% |
| 2016-12-31 | ₩29.81 Billion ≈ $20.20 Million |
+261.22% |
| 2015-12-31 | ₩8.25 Billion ≈ $5.59 Million |
+36.74% |
| 2014-12-31 | ₩6.03 Billion ≈ $4.09 Million |
-25.58% |
| 2013-12-31 | ₩8.11 Billion ≈ $5.50 Million |
-38.66% |
| 2012-12-31 | ₩13.22 Billion ≈ $8.96 Million |
+98.26% |
| 2011-12-31 | ₩6.67 Billion ≈ $4.52 Million |
-16.81% |
| 2010-12-31 | ₩8.02 Billion ≈ $5.43 Million |
-58.48% |
| 2009-12-31 | ₩19.30 Billion ≈ $13.08 Million |
-- |
About GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, whic… Read more